# Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

> **NCT06211114** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Collecting Duct Carcinoma

## Interventions

- **DRUG:** PD-(L)1 inhibitor
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT06211114
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-09
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06211114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06211114, "Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06211114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*